Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069710 | 0.87 | RET (0.36) | CHRNB4CHRNA3CTSKSSTR4SSTR1 | |
| SCHEMBL18347944 | 0.87 | KDM4E (0.33) | CHRNB4CHRNA3KDM4EKDM5AMTNR1A | |
| SCHEMBL19801194 | 0.83 | SSTR4 (0.45) | SSTR4SSTR1 | |
| SCHEMBL15980408 | 0.81 | OGA (0.38) | SSTR4SSTR1 | |
| SCHEMBL24316215 | 0.80 | SSTR4 (0.34) | CHRNB4CHRNA3SSTR4SSTR1KDM4E | |
| SCHEMBL20069720 | 0.80 | SMN1; SMN2 (0.39) | CTSKSSTR4SSTR1KDM5APREP | |
| SCHEMBL12304478 | 0.80 | HTR4 (0.36) | CHRNB4CHRNA3SSTR4 | |
| SCHEMBL20070143 | 0.80 | HSD11B1 (0.40) | CHRNB4CHRNA3CTSKSSTR4SSTR1 | |
| SCHEMBL18347953 | 0.77 | KDM5A (0.45) | SSTR4SSTR1KDM4EKDM5AMTNR1A | |
| SCHEMBL16078081 | 0.77 | KDM5A (0.45) | SSTR4SSTR1KDM4EKDM5AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | CHRNB4 3427/4885CHRNA3 3287/4885CTSK 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.